G. Fattovich et al., Influence of hepatitis delta virus infection on morbidity and mortality incompensated cirrhosis type B, GUT, 46(3), 2000, pp. 420-426
Background-The effect of hepatitis delta virus (HDV) infection on the clini
cal course of cirrhosis type B is poorly defined.
Aims-To investigate the impact of HDV status on morbidity and mortality in
cirrhosis type B.
Patients/Methods-Retrospective cohort study of 200 Western European patient
s with compensated cirrhosis type B followed for a median period of 6.6 yea
rs.
Results-At diagnosis, 20% of patients had antibodies to HDV (anti-HDV); med
ian age was lower in anti-HDV positive cirrhotics (34 v 48 years respective
ly). Kaplan-Meier five year probability of hepatocellular carcinoma (HCC) w
as 6, 10, and 9% in anti-HDV positive/HBeAg negative, anti-HDV negative/HBe
Ag negative, and anti-HDV negative/HBeAg positive cirrhotics respectively;
the corresponding figures for decompensation were 22, 16, and 19% and for s
urvival they were 92, 89, and 83% respectively. Cox regression analysis ide
ntified age, albumin concentration, gamma-globulin concentration, and HDV s
tatus as significant independent prognostic variables. After adjustment for
clinical and serological differences at baseline, the risk (95% confidence
interval) for HCC, decompensation, and mortality was increased by a factor
of 3.2 (1.0 to 10), 2.2 (0.8 to 5.7), and 2.0 (0.7 to 5.7) respectively in
anti-HDV positive relative to HDV negative cirrhotic patients. The adjuste
d estimated five year risk for HCC was 13, 4, and 2% for anti-HDV positive/
HBeAg negative, anti-HDV negative/HBeAg negative, and anti-HDV negative/HBe
Ag positive cirrhotics respectively; the corresponding figures for decompen
sation were 18, 8, and 14% and for survival 90, 95, and 93% respectively.
Conclusions-HDV infection increases the risk for HCC threefold and for mort
ality twofold in patients with cirrhosis type B.